Induced fit and pharmacophore generation approach applied to A2A adenosine receptor antagonists

Arkivoc

Volumn 2006, Issue 8, 2006, Pages 74-82

  Parenti, Marco D ^a   Fioravanzo, Elena ^a   Mabilia, Massimo ^a   Gallo, Grazia ^b   Ciacci, Andrea ^b  

^a SIN Soluzioni Informatiche Sas   (Italy)

^b Sigma Tau SpA   (Italy)

Author keywords

3D QSAR; Adenosine receptor; Docking; Induced fit; Pharmacophore generation

Indexed keywords

EID: 33745584786     PISSN: 14246376     EISSN: 14246376     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Poulsen, S.-A.; Quinn, R.J. Adenosine Receptors: New Opportunities for Future Drugs. Bioorg.Med. Chem. 1998, 6, 619.
2. Fredholm, B.B.; Abbracchio, M.P.; Burnstock, G.; Daly, J.W.; Harden, K.; Jacobson, K.A.; Leff, P.; Williams, M. Nomenclature and Classification of Purinoreceptors. Pharm. Rew. 1994, 46, 143-156.
3. Fredholm, B. B. Adenosine receptors as targets for drug development. Drug News Perspect. 2003, 16, 283-289.
4. 2A Agonists and Antagonists. J. Med. Chem. 2003, 46, 4847.
5. Schrödinger Suite 2006 Induced Fit Docking protocol; Glide version 4.0, Schrödinger, LLC, New York, NY, 2005;
6. Prime version 1.5, Schrödinger, LLC, New York, NY, 2005.
7. Phase, version 2.0, Schrödinger, LLC, New York, NY, 2005.
8. Sherman, W.; Day, T.; Jacobson, M.P.; Friesner, R.A.; Farid, R. Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects. J. Med. Chem. 2006, 49, 534.
9. Lovell, S.C.; Davis, I.W.; Arendall III, W.B.; De Bakker, P.I.W.; Word, J.M.; Prisant, M.G.; Richardson, J.S.; Richardson, D.C. Structure validation by Cα geometry: φ/ψ and Cβ deviation. Proteins: Structure, Function & Genetics. 2002, 50, 437.
10. 2A Adenosine Receptor Antagonists: A Study on the Importance of Modifications at the Side Chain on the Activity and Solubility. J. Med. Chem. 2002, 45, 115.
11. 2A and A3 Adenosine Receptors Antagonists. J. Med. Chem. 2003, 46, 1229.
12. Yan, L.; Muller, C.E. Preparation, Properties, Reactions, and Adenosine Receptor Affinities of Sulfophenylxanthine Nitrophenyl Esters: Toward the Development of Sulfonic Acid Prodrugs with Peroral Bioavailability. J. Med. Chem. 2004, 47, 1031.
13. Baraldi, P.G.; Tabrizi, M.A.; Preti, D.; Bovero, A.; Romagnoli, R.; Fruttarolo, F.; Zaid, N.A.; Moorman, A.; Varani, K.; Gessi, S.; Merighi, S.; Borea, P.A. Design, Synthesis, and Biological Evaluation of New 8-Heterocyclic Xanthine Derivatives as Highly Potent and Selective Human A2B Adenosine Receptor Antagonists. J. Med. Chem. 2004, 47, 1434.
14. 2a Receptor Antagonists. J. Med. Chem. 2004, 47, 4291.
15. 2A Receptor Antagonists. J. Med. Chem. 2004, 47, 6218.
16. Van den Nieuwendijk, A.M.C.H.; Pietra, D.; Heitman, L.; Goblyos, A.; Ijzerman, A.P. Synthesis and Biological Evaluation of 2,3,5-Substituted [1,2,4]Thiadiazoles as Allosteric Modulators of Adenosine Receptors. J. Med. Chem. 2004, 47, 663.
17. 2a Receptor Antagonists. J. Med. Chem. 2005, 48, 2009.
18. 2a receptor antagonists: comparison of three core heterocycles. Bioorg. Med. Chem. Lett. 14 (2004) 4831-4834.
19. 2a receptor antagonists. Bioorg. Med. Chem. Lett. 14 (2004) 4835-4838.
20. 2A adenosine receptor antagonists. Bioorg. Med. Chem. Lett. 15 (2005) 511-515.
21. 2a) antagonist. Bioorg. Med. Chem. Lett. 15 (2005) 1333-1336.